S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead

Akebia Therapeutics (AKBA) Stock Forecast & Price Target

$1.07
+0.01 (+0.94%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.02
$1.09
50-Day Range
$0.80
$1.17
52-Week Range
$0.28
$1.84
Volume
1.19 million shs
Average Volume
1.26 million shs
Market Capitalization
$201.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Akebia Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$4.50
320.56% Upside
High Forecast$5.00
Average Forecast$4.50
Low Forecast$4.00
TypeCurrent Forecast
12/2/22 to 12/2/23
1 Month Ago
11/2/22 to 11/2/23
3 Months Ago
9/3/22 to 9/3/23
1 Year Ago
12/2/21 to 12/2/22
Consensus Rating
Buy
Buy
Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
0 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.50$3.75$3.75$1.75
Predicted Upside320.56% Upside220.51% Upside226.09% Upside128.52% Upside
Get Akebia Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.


AKBA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKBA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akebia Therapeutics Stock vs. The Competition

TypeAkebia TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside320.56% Upside647.64% Upside2,867.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/29/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$4.00+316.66%
11/17/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$3.75 ➝ $5.00+405.61%
5/31/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight
(Data available from 12/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AKBA Price Target - Frequently Asked Questions

What is Akebia Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Akebia Therapeutics stock is Buy based on the current 3 buy ratings for AKBA. The average twelve-month price prediction for Akebia Therapeutics is $4.50 with a high price target of $5.00 and a low price target of $4.00. Learn more on AKBA's analyst rating history.

Do Wall Street analysts like Akebia Therapeutics more than its competitors?

Analysts like Akebia Therapeutics more than other Medical companies. The consensus rating for Akebia Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how AKBA compares to other companies.

Does Akebia Therapeutics's stock price have much upside?

According to analysts, Akebia Therapeutics's stock has a predicted upside of 361.80% based on their 12-month stock forecasts.

What analysts cover Akebia Therapeutics?

Akebia Therapeutics has been rated by BTIG Research, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AKBA) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -